Germany's 38 Billion Euro Back Pain Crisis: New Push for Movement Over Pills and Passivity
Published on 06/19/2026 at 12:22 | Redaktion boerse-global.de
Chronically ill patients in Germany cost the healthcare system an estimated 38 billion euros each year. More than 12 million people in the country live with persistent pain – a figure that represents over 30 percent of the global total. Yet the way these patients are treated is shifting away from passive therapies and toward active, movement-based care.
On 18 June 2026, the Gemeinsame Bundesausschuss (G-BA), Germany's highest decision-making body in outpatient healthcare, updated the requirements for its Disease Management Program (DMP) covering chronic back pain. The revision draws on an analysis from the Institute for Quality and Efficiency in Health Care (IQWiG), which examined 425 recommendations from 11 clinical guidelines. Central to the change is an effort to break what experts call "fear-avoidance behavior" – the tendency of patients to avoid movement due to fear of pain.
No contracts yet, despite millions affected
Despite the updated rules, practical implementation lags. Health insurers have not yet signed care contracts for chronic back pain, obesity, or depression. That means the new DMP guidelines remain theoretical for the time being.
Music therapy delivers measurable relief
New evidence bolsters the case for non-drug approaches. A U.S. study involving 1,203 patients, whose results were also released on 18 June, found that active music-making or singing produced a statistically significant reduction in pain of at least two points on a ten-point scale. The finding reinforces the G-BA's emphasis on patient activity rather than passive intervention.
Barmer rolls out hybrid physio-digital program
In a separate development, the Barmer health insurer announced it will offer the GLA:D therapy concept for members with knee and hip osteoarthritis starting in July 2026 in Berlin and Brandenburg. Developed in Denmark, the program combines conventional physiotherapy with a digital app. Its aim: reduce pain through targeted exercise and avoid surgical procedures. A gradual nationwide rollout is already underway.
Osteopathy questioned, drugs dominate
Not all alternative therapies fare well under scientific scrutiny. The IGeL-Monitor, which evaluates insurance-covered individual health services, again rated osteopathy for non-specific low back pain as "unclear" in June. The evidence for a clinically meaningful benefit over placebo remains weak, the monitor concluded. Yet patients continue to pay between 80 and 150 euros per session – this despite the fact that osteopathy is still not a state-recognized profession in Germany.
Meanwhile, pharmacological treatment remains the dominant approach. A study in Pain Management Nursing, analyzing data from 3,000 patients recorded between 2021 and 2023, found that roughly 86 percent of chronic pain patients received analgesics. Physiotherapy was used in only 40 percent of cases, and other non-drug therapies in fewer than 10 percent.
Advances in neurology and depression
Promising research extends beyond musculoskeletal pain. A U.S. trial of spinal cord stimulation in stroke patients, published on 17 June, showed that arm strength improved by 36 percent after four weeks of treatment, along with a reduction in spasticity.
For Restless Legs Syndrome (RLS), experts presented an updated treatment algorithm on 18 June. It recommends checking iron status and naming gabapentinoids as the preferred therapy. The authors warned that dopamine agonists carry a risk of symptom augmentation.
Long-term data from the EPIsoDE study by the Central Institute of Mental Health in Mannheim demonstrated that psilocybin combined with psychotherapy produced stable improvement in patients with treatment-resistant depression over a 12-month observation period.
As Germany grapples with the enormous economic and human toll of chronic pain, the emerging picture is clear: the system is edging away from passivity and toward active, evidence-based intervention – even if the full shift in practice is still a work in progress.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
